×
About 7,023 results

ALLMedicine™ Follicular Lymphoma Center

Research & Reviews  2,054 results

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03789240

May 13th, 2022 - Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin s lymphoma (NHL) with a highly variable clinical course across patients Standard frontline therapy for FL includes a monoclonal anti-CD20 antibody with or without chemoth...

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05371093

May 12th, 2022 - Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up ass...

Loss of RARRES1 function Promotes Follicular Lymphomagenesis and Inhibits B cell Differ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066096
International Journal of Biological Sciences; Patel J, Xun D et. al.

May 12th, 2022 - Retinoic acid receptor responder 1 (RARRES1) is among the most commonly methylated loci in multiple cancers. RARRES1 regulates mitochondrial and fatty acid metabolism, stem cell differentiation, and survival of immortalized cell lines in vitro. He...

Targeting Apoptosis in ALL.
https://doi.org/10.1007/s11899-022-00661-9 10.1038/bcj.2017.53 10.1056/NEJMoa1609783 10.1182/blood-2017-08-798322 10.1056/NEJMoa1509277 10.1016/S0140-6736(21)01222-8 10.1200/JCO.2016.69.3531 10.1056/NEJMoa1709866 10.1056/NEJMoa2012971 10.1056/NEJMoa1815281 10.1056/NEJMoa1713976 10.1200/JCO.18.01600 10.1158/2159-8290.CD-12-0208 10.1158/0008-5472.CAN-14-1849 10.1182/blood-2016-09-738070 10.1158/2159-8290.CD-20-1465 10.1038/nrm2308 10.1126/science.3874430 10.1042/bst0280051 10.1038/nrm3722 10.1038/nature19830 10.1182/blood-2015-10-675009 10.1038/cddis.2014.525 10.1038/s41375-018-0201-2 10.1182/blood-2015-08-661702 10.1016/S1470-2045(08)70314-0 10.1002/ajh.26144 10.1182/blood-2007-06-098012 10.1016/j.ccr.2006.03.027 10.1016/j.cell.2012.08.038 10.1126/science.1206727 10.1158/2159-8290.CD-14-0353 10.1038/srep27696 10.1111/ejh.13492 10.1186/s13045-021-01079-1 10.1158/0008-5472.CAN-07-5836 10.1158/1078-0432.CCR-07-4622 10.1016/S1470-2045(10)70261-8 10.1038/nm.3048 10.1056/NEJMoa1513257 10.1182/blood-2019-129988 10.1016/S1470-2045(18)30011-1 10.1182/blood-2021-153826 10.1016/S2152-2650(20)30458-4 10.1002/ajh.26175 10.1038/s41408-022-00621-9 10.1182/blood-2021-153621 10.1155/2018/6092646 10.1016/j.hemonc.2019.10.002 10.1080/10428194.2021.1957876 10.1016/j.clml.2018.07.289 10.1016/j.clml.2019.09.608 10.1200/PO.18.00127 10.1007/s00277-019-03902-9 10.1002/ccr3.3041 10.1007/s00277-021-04530-y 10.1080/10428194.2021.1897807 10.1053/j.seminhematol.2008.09.001
Current Hematologic Malignancy Reports; Smith WM, Reed DR

May 11th, 2022 - While the treatment of acute lymphoblastic leukemia (ALL) has improved significantly over the last 30 years, the majority of adult patients will have their disease relapse. The BCL-2 gene was initially discovered from follicular lymphoma research;...

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients ...
https://doi.org/10.1182/bloodadvances.2021006520
Blood Advances; Stathis A, Mey UJM et. al.

May 11th, 2022 - This phase I study evaluated safety, tolerability and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two dose levels of venetocl...

see more →

Guidelines  9 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for...
https://doi.org/10.1016/j.annonc.2020.11.008
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Ghielmini M et. al.

Nov 30th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|therapeutic use,diagnosis,epidemiology,therapy,diagnosis,therapy,the...

The investigation and management of follicular lymphoma.
https://doi.org/10.1111/bjh.16872
British Journal of Haematology; McNamara C, Montoto S et. al.

Jun 25th, 2020 - The investigation and management of follicular lymphoma.|2020|McNamara C,Montoto S,Eyre TA,Ardeshna K,Burton C,|diagnosis,therapy,

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

Non-Hodgkin's lymphomas, version 2.2014.
https://doi.org/10.6004/jnccn.2014.0086
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Jun 14th, 2014 - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for app...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  130 results

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03789240

May 13th, 2022 - Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin s lymphoma (NHL) with a highly variable clinical course across patients Standard frontline therapy for FL includes a monoclonal anti-CD20 antibody with or without chemoth...

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05371093

May 12th, 2022 - Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up ass...

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03888105

May 10th, 2022 - Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by indepen...

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03817853

May 10th, 2022 - This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with pre...

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and P...
https://clinicaltrials.gov/ct2/show/NCT04246086

May 6th, 2022 - This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab + lenalidomide, glofitamab + lenalidomide, and glofitamab + lenalidomide + obinutuzumab in participants with relapsed or refractory (R/R) follicul...

see more →

News  600 results

CAR-T Outcomes Similar Among Black, Hispanic, White, Asian Patients
https://www.medscape.com/viewarticle/973727

May 12th, 2022 - NEW YORK (Reuters Health) - Black and Hispanic cancer patients who underwent CAR-T therapy at a single center had comparable outcomes to their white and Asian counterparts, researchers say. "We were not surprised at the outcome, but our findings h...

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma
https://www.onclive.com/view/match-adjusted-comparison-shows-comparable-efficacy-outcomes-for-axi-cel-and-tisa-cel-in-follicular-lymphoma

Apr 25th, 2022 - Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel (Yescarta; axi-cel) in ZUMA-5 trial (NCT03105336) vs those treated with tisagenlecleucel (Kymriah; tisa-cel) in ELARA (NCT03568461) show...

see more →

Patient Education  1 results see all →